Classic congenital adrenal hyperplasia, more commonly called classic CAH, is when there is an enzyme missing in the adrenal gland, which causes the body to have the inability to make enough cortisol.

For the first time ever, the FDA has approved a treatment specifically for people with classic congenital adrenal hyperplasia (CAH), a genetic condition that affects the adrenal glands.

Boys and young adult male patients with congenital adrenal hyperplasia receiving glucocorticoid treatment have lower bone ...

On Dec 12, 2024, the US Food and Drug Administration (FDA) approved crinecerfont for adults and paediatric patients with ...

Sexual precocity and a testicular mass can result from a Leydig cell tumor or from simple virilizing CAH with adrenal rests in the testes. These diagnoses are usually distinguished by very high ...

Other symptoms of PCOS include: Nonclassic congenital adrenal hyperplasia (NCCAH) is a genetic disorder. The late-onset form has similar symptoms to PCOS. It is due to a missing enzyme responsible ...

The use of dehydroepiandrosterone sulfate to determine an adrenal insufficiency diagnosis has similar ... releasing factor type 1 receptor to treat congenital adrenal hyperplasia, according ...

HBM Alpha Therapeutics Inc. signed a potential $395 million licensing deal Feb. 26 with an unnamed “business partner” for its endocrine asset, HAT-001, adding another contender to the congenital ...

Neurocrine Biosciences announced that the FDA has approved crinecerfont as an adjunct to glucocorticoid replacement to control androgens for patients with congenital adrenal hyperplasia.